OCU410ST (AAV5-hRORA)

About Ocugen

Ocugen is a clinical-stage biotech focused on developing transformative gene therapies for blindness diseases, with a lead program in Phase 3 for retinitis pigmentosa. The company leverages a unique modifier gene therapy platform designed to address multiple genetic mutations with a single treatment, offering a potential paradigm shift in ophthalmology. Ocugen also maintains a portfolio of inhaled vaccines and biologics, supported by strategic partnerships with Bharat Biotech and CanSinoBIO. The company is led by a seasoned team with deep experience in biopharmaceutical development and commercialization.

Therapeutic Areas

Other Stargardt Disease Drugs